Skip to content

Study · Animal study (in vivo) · rat · 1996

7 results

Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.

Tomas FM, Lemmey AB, Read LC, Ballard FJ

The Journal of endocrinology1 Jul 1996Cited by 12 (Europe PMC)

PMID8708565 (opens in a new tab)DOI10.1677/joe.0.1500077 (opens in a new tab)PepBankPUB-08708565
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, continuously infused LR3IGF-I was generally 1.5- to 2-fold more potent than IGF-I for changes in body weight gain.

    In plain wordsIn rats, continuous LR3IGF-I was generally 1.5 to 2 times more potent than IGF-I for body weight gain.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseBody weight gain with continuous infusion
    Study

    ratn: not reported in source

    Comparator
    IGF-I
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    320 and 400 micrograms/day · continuous subcutaneous infusion · 7 daysAs given in this study (rat).

    Measurements

    Potency relative to IGF-I
    1.5 to 2 fold
    continuous infusion

    Source sentences

    Summary
    When infused continuously LR3IGF-I was generally 1.5- to 2-fold more potent than IGF-I for changes in body weight gain, visceral organ weights and feed use efficiency.
    2 context sentences
    Summary · context
    Experiments were performed in normal growing rats (150 g body weight) and in rats made catabolic by dexamethasone infusion (20 micrograms/day).
    Summary · context
    IGFs or vehicle were delivered subcutaneously for 7 days either by continuous infusion via osmotic pumps or by injection once or twice daily at 320 and 400 micrograms/day in normal and catabolic rats respectively.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, continuously infused LR3IGF-I was generally 1.5- to 2-fold more potent than IGF-I for changes in visceral organ weights.

    In plain wordsIn rats, continuous LR3IGF-I was generally 1.5 to 2 times more potent than IGF-I for organ weights.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseVisceral organ weights with continuous infusion
    Study

    ratn: not reported in source

    Comparator
    IGF-I
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    320 and 400 micrograms/day · continuous subcutaneous infusion · 7 daysAs given in this study (rat).

    Measurements

    Potency relative to IGF-I
    1.5 to 2 fold
    continuous infusion

    Source sentences

    Summary
    When infused continuously LR3IGF-I was generally 1.5- to 2-fold more potent than IGF-I for changes in body weight gain, visceral organ weights and feed use efficiency.
    2 context sentences
    Summary · context
    Experiments were performed in normal growing rats (150 g body weight) and in rats made catabolic by dexamethasone infusion (20 micrograms/day).
    Summary · context
    IGFs or vehicle were delivered subcutaneously for 7 days either by continuous infusion via osmotic pumps or by injection once or twice daily at 320 and 400 micrograms/day in normal and catabolic rats respectively.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, continuously infused LR3IGF-I was generally 1.5- to 2-fold more potent than IGF-I for changes in feed use efficiency.

    In plain wordsIn rats, continuous LR3IGF-I was generally 1.5 to 2 times more potent than IGF-I for feed use efficiency.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseFeed use efficiency with continuous infusion
    Study

    ratn: not reported in source

    Comparator
    IGF-I
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    320 and 400 micrograms/day · continuous subcutaneous infusion · 7 daysAs given in this study (rat).

    Measurements

    Potency relative to IGF-I
    1.5 to 2 fold
    continuous infusion

    Source sentences

    Summary
    When infused continuously LR3IGF-I was generally 1.5- to 2-fold more potent than IGF-I for changes in body weight gain, visceral organ weights and feed use efficiency.
    2 context sentences
    Summary · context
    Experiments were performed in normal growing rats (150 g body weight) and in rats made catabolic by dexamethasone infusion (20 micrograms/day).
    Summary · context
    IGFs or vehicle were delivered subcutaneously for 7 days either by continuous infusion via osmotic pumps or by injection once or twice daily at 320 and 400 micrograms/day in normal and catabolic rats respectively.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, LR3IGF-I given by once-daily injection remained more potent than IGF-I in several growth-related effects.

    In plain wordsIn rats, LR3IGF-I given by daily injection stayed more potent than IGF-I in several effects.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseGrowth-related effects with once-daily injection
    Study

    ratn: not reported in source

    Comparator
    IGF-I
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    320 and 400 micrograms/day · once-daily subcutaneous injection · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Notably, LR3IGF-I remained more potent than IGF-I in several of these effects even when the peptides were given by once-daily injection.
    2 context sentences
    Summary · context
    Experiments were performed in normal growing rats (150 g body weight) and in rats made catabolic by dexamethasone infusion (20 micrograms/day).
    Summary · context
    IGFs or vehicle were delivered subcutaneously for 7 days either by continuous infusion via osmotic pumps or by injection once or twice daily at 320 and 400 micrograms/day in normal and catabolic rats respectively.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In dexamethasone-treated rats, N tau-methylhistidine excretion was reduced to a threefold greater extent by injected LR3IGF-I than by injected IGF-I.

    In plain wordsIn rats with induced muscle breakdown, injected LR3IGF-I cut a muscle breakdown marker three times more than injected IGF-I.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseN tau-methylhistidine excretion in dexamethasone-treated rats
    Study

    ratn: not reported in source

    Comparator
    IGF-I
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    400 micrograms/day · subcutaneous injection · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    In addition, N tau-methylhistidine excretion by dexamethasone-treated rats was reduced to a threefold greater extent by injected LR3IGF-I than by injected IGF-I.
    2 context sentences
    Summary · context
    Experiments were performed in normal growing rats (150 g body weight) and in rats made catabolic by dexamethasone infusion (20 micrograms/day).
    Summary · context
    IGFs or vehicle were delivered subcutaneously for 7 days either by continuous infusion via osmotic pumps or by injection once or twice daily at 320 and 400 micrograms/day in normal and catabolic rats respectively.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In dexamethasone-treated rats, LR3IGF-I was barely equipotent with IGF-I for reversal of carcass muscle loss.

    In plain wordsIn rats with induced muscle loss, LR3IGF-I was barely as potent as IGF-I at reversing muscle loss.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeReversal of carcass muscle loss in dexamethasone-treated rats
    Study

    ratn: not reported in source

    Comparator
    IGF-I
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    400 micrograms/day · subcutaneous · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Notwithstanding these effects, LR3IGF-I was barely equipotent with IGF-I for reversal of carcass muscle loss in dexamethasone-treated rats.
    2 context sentences
    Summary · context
    Experiments were performed in normal growing rats (150 g body weight) and in rats made catabolic by dexamethasone infusion (20 micrograms/day).
    Summary · context
    IGFs or vehicle were delivered subcutaneously for 7 days either by continuous infusion via osmotic pumps or by injection once or twice daily at 320 and 400 micrograms/day in normal and catabolic rats respectively.

Studies that did not test the peptide alone1

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 07AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome

    In rats, continuous infusion of IGFs, including LR3IGF-I and IGF-I, showed greater efficacy than either injection mode, especially for anti-catabolic actions.

    In plain wordsIn rats, giving IGFs by continuous infusion worked better than by injection, especially against muscle breakdown.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseContinuous infusion versus injection of IGFs
    Study

    ratn: not reported in source

    Comparator
    Injection of IGFs
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    As expected, continuous infusion of IGFs showed greater efficacy than either of the injection modes especially in its anti-catabolic actions.
    2 context sentences
    Summary · context
    Experiments were performed in normal growing rats (150 g body weight) and in rats made catabolic by dexamethasone infusion (20 micrograms/day).
    Summary · context
    IGFs or vehicle were delivered subcutaneously for 7 days either by continuous infusion via osmotic pumps or by injection once or twice daily at 320 and 400 micrograms/day in normal and catabolic rats respectively.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.